Please assess the completion status of the following clinical trial:

Trial Title: Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-III HER-2 positive breast cancer~* Receiving adjuvant therapy with trastuzumab~* Provide informed consent~* Exhibit LV dysfunction as evidenced by either~  * LVEF between 40% and the lower limit for normal (i.e. \<54% in women or \< 52% in men18), or~ * LVEF within normal limits (i.e. ≥54% in women or ≥52% in men) and NYHA class II heart failure symptoms within the past year, or~ * A fall in LVEF of ≥15% from baseline~Exclusion Criteria:~Patients will not be eligible for SCHOLAR if they have any of the following:~* NYHA class III or IV heart failure~* Systolic blood pressure \<90mmHg~* Current use of both ACE-I/angiotensin receptor blocker and beta-blocker~* Contra-indication to both ACE-I/angiotensin receptor blocker and beta-blocker

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heart failure (Type: EXPERIMENTAL): Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers

Based on this trial design, predict the completion outcome and termination type (if applicable).